Mazen Animal Health, Inc. Announces Successful Sow Study

166

Lactogenic Immunity Demonstrated after Oral Vaccination.

Mazen today announced the successful completion of a sow study designed to demonstrate lactogenic immunity induced protection in newborn pigs after oral vaccination against porcine epidemic diarrhea virus, (PEDv). The company is developing orallydelivered animal vaccines administered in the feed that revolutionize animal disease prevention.

In the study, conducted at VRI in Ames, Iowa, gestating sows were vaccinated orally with either the vaccine or a negative control. Four-day old piglets were then challenged using a proven reproducible and highly virulent PEDv challenge model. Mazen’s oral vaccine was statistically better than the control arm. The statistical difference in mortality between the vaccinated and control groups in this 4 sow-per-group study are consistent with successful efficacy trials for vaccine licensure. Mazen has proposed that an orally deliveredvaccine, providing enteric mucosal induced immunity may provide better protection in herds affected by PEDvinfection.

A recently conducted vaccine efficacy trial conducted by our group provided compelling data supporting the efficacy of Mazen Animal Health’s PEDv vaccine constructs.”, said Ryan Saltzman, DVM, VRI Managing Veterinarian. VRI has conducted numerous PEDv vaccine trials ever since the introductionof the virus into the US swine population.To date, Mazen’s vaccine constructs appear to be the most promising in regard to improving piglet survivability and condition following a virulent PEDv challenge.

These data demonstrate that oral vaccination works,” said Jenny Filbey, CEO and Board Chair of Mazen. Our team is energized to move the PEDv program forward to commercialization with a robust pipeline in development behind it.We are now well positioned to raise our Series Around.

The $2M Series Seed, which closed in April, 2021,is fundingf urther regulatory development for Mazen’s lead PEDvvaccine candidate, scale up of pipeline products, and preparations for registration studies. Mazenisraising Series A funding,which will be used to complete the registration studies for licensure of the PEDvoral vaccine, build the pipelineand expand the team and capabilities.

About Mazen Animal Health, Inc.

Mazen is developing orallydelivered animal vaccines that revolutionize animal disease prevention. Mazen provides elegant solutions to the challenges associated with injectable vaccinesand offerscustomers (1) increased production system ROI improving the economic & labor thresholds that control the vaccination decision today; (2) a safer method of vaccine administration for both animals and workers; (3) optimized vaccine efficacy includingmucosal and systemic coverage; and (4) vaccines with a global reach because of ambient temperature stability and ease of delivery.Mazen has successfullycompleteda lactogenic immunity study with the PEDV oral vaccine candidate and is now planningfor registration studies. www.mazenanimalhealth.com